argenx stock
Price history
+7.66% over the period1 year: from $891.73 (November 13, 2025) to $960.04 (November 13, 2026), +7.66%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $960.04 |
| October 30, 2026 | $892.87 |
| September 30, 2026 | $958.91 |
| August 31, 2026 | $1,031.66 |
| July 31, 2026 | $853.82 |
| June 30, 2026 | $927.77 |
| May 29, 2026 | $835.99 |
| April 30, 2026 | $781.72 |
| March 31, 2026 | $730.25 |
| February 27, 2026 | $766.92 |
| January 30, 2026 | $840.50 |
| December 31, 2025 | $840.95 |
| November 28, 2025 | $911.98 |
| November 13, 2025 | $891.73 |
At a glance
The company
Commercial-stage biopharma company developing therapies for autoimmune diseases including VYVGART and VYVGART HYTRULO
Latest results
Quarter to September 30, 2026 · EPS $7.80 (estimate $7.67)
TickerLandia's take on argenx
- Priced in line with similar companies: trailing 12-month P/E 33 vs 35 (−4%) in a group of 7.
- Strong point: Financial strength (84/100 in its group). Weak point: Earnings stability (25/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−10.51% from the 52-week high
Analysts · 25 analysts
Average target$1,144.74+19.24% vs. price
Buy 22 · Hold 3 · Sell 0 · Buy
TickerLandia Fingerprint: argenx
Compared with similar companies: very high financial strength and very high growth.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricehigh61
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 33.3 37 Forward P/E 28.8 52 Price/book 178.3 99 Price/sales 10.2 55 Profitabilityhigh71
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 31.9% 78 Gross margin 59.8% 35 ROA 11.6% 86 Net margin 31.7% 81 ROE 23.6% 77 Earnings stabilitylow25
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3,116.6% 6 Loss-making yearscounts in reverse: lower means more earnings stability 3 of 5 annual reports 43 Growthvery high84
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +52.10% 78 Earnings growth (year over year) +50.60% 75 Average revenue growth (3 years) +650.40% 97 Financial strengthvery high84
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.01 91 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −3.24 91 Interest coverage 332.2 88 Current ratio 5.12 68 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong69
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) +17.74% 76 Distance from 200-day average +11.60% 73 1-year return +7.66% 43 Relative strength (3 months) +15.55% 85 Riskaverage52
How much the price swings.
Metric Value Position in group Volatility (60 days) 40.4% 64 Beta (1 year) 0.53 42 Maximum drawdown (12 months) 28.6% 49
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
argenx is in line with similar companies
argenx's P/E (trailing 12 months): 33.3, in line with the median of a group of 7 similar companies (34.7).
Compared with 7 similar companies
| Metric | argenx | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 33.3 | Middle | |
| Forward P/E | 28.8 | Middle | |
| Operating margin | 31.9% | Middle | |
| ROE | 23.6% | High | |
| Debt/equity | 0.01 | Low |
Grey band: the middle half of the group; tick: the median; dot: argenx. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$1.75B
Latest quarter · Q3 2026
Net income
$506M
Latest quarter · Q3 2026
Quarterly net margin
28.9%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $60.37B
- P/E
- 33.3
- EPS
- $28.87
- Volume
- 225.89K
- Daily trading
- €337.3M
- Dividend yield
- 0.00%
How argenx is changing
All resultsRevenue grew 152.5% a year on average over the last 5 years
Operating margin rose from −7,184.7% to 24.9%
Less cash than profit: free cash flow equal to 9% of net income
Returns
argenx returns
$1,000 invested in argenx 5 years ago, on November 15, 2021, would be worth $3,187 today: +218.74% in total, +26.13% per year. This is the price return only: dividends are excluded.
| Period | argenx | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +19.61% | −3.12% | $1,196 |
| 6 months | +19.60% | +1.58% | $1,196 |
| Year to date | +14.16% | +10.46% | $1,142 |
| 1 year | +7.66% | +12.23% | $1,077 |
| 3 years | +95.87% | +71.41% | $1,959 |
| 5 years | +218.74% | +61.48% | $3,187 |
Over the last 6 months it has done better than 54% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
argenx: technical analysis
argenx is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 9.3% below its all-time closing high ($1,058.90, August 27, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 59
- Between 30 and 70
- vs 200-session average
- +11.60%
Support and resistance
Price areas where argenx has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$960.04
- Support$934.56−2.65%5 touches, last on September 23, 2026
- Support$887.39−7.57%3 touches, last on August 7, 2026
- Support$855.61−10.88%3 touches, last on April 17, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.53
- Volatility (60 sessions, annualised)
- 40.4%
- Largest fall in the last year
- −28.58%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
argenx: seasonality
Average monthly price change over 10 years
Over the last 10 years, the strongest month for argenx has been November: +11.64% on average, positive in 7 years out of 9. The weakest has been September: −2.70% on average, positive in 4 years out of 10.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.79% | +0.02% | 5 of 9 |
| February | +2.70% | −1.22% | 3 of 9 |
| March | −2.22% | −4.78% | 4 of 9 |
| April | +3.72% | +4.11% | 7 of 9 |
| May | +6.11% | +0.21% | 5 of 9 |
| June | +5.94% | +5.31% | 8 of 10 |
| July | +7.01% | +1.65% | 6 of 10 |
| August | +3.66% | +1.94% | 7 of 10 |
| September | −2.70% | −4.36% | 4 of 10 |
| October | +2.65% | +3.43% | 6 of 10 |
| November | +11.64% | +11.42% | 7 of 9 |
| December | +11.60% | −0.25% | 4 of 9 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
argenx and its competitors
With revenue of $4.2 billion, argenx SE is a commercial-stage biopharmaceutical company that develops therapies for autoimmune diseases. It offers VYVGART for generalized myasthenia gravis and immune thrombocytopenia, and VYVGART HYTRULO for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Its development programs cover a range of other autoimmune conditions, and it has partnerships and license agreements with Zai Lab, Halozyme Therapeutics, OncoVerity and AbbVie. The United States accounted for 83.2% of revenue, with the remainder coming from Japan, China and the rest of the world.
- Headquarters
- Amsterdam, Netherlands
- Employees
- 1,863
- Founded
- 2008
- Chief executive
- Karen Massey
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| argenxARGX | $60.37B | 31.9% | 33.3 | +19.60% |
| BeOne MedicinesONC | $47.58B | 17.8% | 53.4 | +31.59% |
| ModernaMRNA | $90.38B | -80.8% | — | +343.02% |
| Royalty PharmaRPRX | $39.85B | 64.4% | 45.3 | +30.16% |
| Revolution MedicinesRVMD | $37.27B | -853.0% | — | +14.91% |
| Regeneron PharmaceuticalsREGN | $98.84B | 30.4% | 21.1 | +32.73% |
Same industry or related industries, similar size. Compare argenx with its competitors · Full profile
